Latest Mast Therapeutics Inc (MSTX) Headlines
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista") announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 06, 12:39PM CST
These under-$10 stocks look ready to trade higher from current levels.
Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"), a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial."
Mast Therapeutics acquires Aires Pharmaceuticals in all-stock transaction
M2 - Fri Feb 28, 3:43AM CST
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) disclosed on Thursday the completion of the acquisition of Aires Pharmaceuticals in an all-stock transaction.
Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
PR Newswire - Thu Feb 27, 1:18PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension.
Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd
PR Newswire - Tue Feb 25, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen & Co. 34th Annual Healthcare Conference on Monday, March 3, 2014 at 4:50 p.m. Eastern time at The Boston Marriott Copley Place Hotel in Boston.
Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188
PR Newswire - Mon Feb 24, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, consistent with its prior guidance, it has initiated international enrollment in EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, with clinical sites now open in multiple foreign jurisdictions with high rates of hospitalization for sickle cell disease. The Company previously reported that it had met its goal of having 40 U.S. sites open by the end of 2013 and is on-track to opening an additional 30 sites outside of the U.S. by the end of 2014.
Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
PR Newswire - Tue Feb 18, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 (low dose and high dose) in a model of chronic heart failure.
Mast Therapeutics to acquire Aires Pharmaceuticals
M2 - Tue Feb 11, 6:52AM CST
US-based biopharmaceutical company Mast Therapeutics Inc (NYSE MKT:MSTX) said on Monday that it has signed a definitive agreement to acquire Aires Pharmaceuticals Inc in exchange for Mast's common stock in an all-stock transaction.
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.
PR Newswire - Mon Feb 10, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.
Vista Partners Publishes February 2014 Macroeconomic & Investment Newsletter
Marketwire - Wed Feb 05, 8:01AM CST
Vista Partners ("Vista") announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of February. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
PR Newswire - Wed Jan 08, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided an update on the status of EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease. Consistent with prior guidance, the Company announced that 40 clinical sites were opened in the U.S. by year-end 2013. In addition, clinical sites are expected to open in at least three countries outside the U.S. in the first quarter of 2014, leading to a total of approximately 30 ex-U.S. sites open by the end of 2014. Overall study enrollment is consistent with internal projections and the Company affirmed prior guidance that it expects to complete full enrollment for the trial by the end of 2015.
Mast Therapeutics To Present At The OneMedForum Emerging Company Finance Conference On January 14
PR Newswire - Tue Jan 07, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the OneMedForum Emerging Company Finance Conference on Tuesday, January 14th, 2014 at 2:10 p.m. Pacific time at The Westin Hotel in San Francisco.
Mast Therapeutics Announces Positive Data In Model Of Heart Failure
PR Newswire - Mon Jan 06, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output. Notably, a single two-hour infusion of MST-188 resulted in improvements that were significant immediately (at the end of MST-188 administration) and remained significant at one week (and, in some cases, at two weeks) after MST-188 administration.
Vista Partners Updates Coverage on Mast Therapeutics, Inc.; Price Target $2.25
Marketwire - Wed Dec 18, 8:15AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"), a publicly traded biopharmaceutical company headquartered in San Diego, CA, with a twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "MSTX began dosing in its pivotal Phase 3 clinical study of MST-188 (purified poloxamer 188) in sickle cell disease in May. MSTX believes that it is currently the only company with a new molecular entity in a Phase 3 clinical trial for the treatment of sickle cell disease, a disease with significant unmet needs and which has been experiencing unprecedented interest from strategic partners, acquisition oriented suitors, and financial investors." Mr. Silver continued, "MSTX plans to develop MST-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease. Peripheral arterial disease affects an estimated 8 to 12 million people in the United States. The planned Phase 2 trial in ALI is scheduled to commence in the first quarter of 2014." Mr. Silver concludes, "MSTX anticipates that cash as of September 30, 2013 or $0.48/share, should be sufficient to fully fund all planned clinical trials."
Mast Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3
PR Newswire - Tue Nov 26, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 25th Annual Piper Jaffray Healthcare Conference, on Tuesday, December 3rd, 2013 at 4:30 p.m. Eastern time in the Rutherford Room at The New York Palace Hotel in New York.
FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
PR Newswire - Wed Nov 13, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the U.S. Food and Drug Administration (FDA) has designated MST-188 for the treatment of acute limb ischemia as an orphan drug.
Mast Therapeutics Reports Third Quarter 2013 Financial Results
PR Newswire - Mon Nov 04, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended September 30, 2013.
5 Stocks Under $10 on the Verge of Breakouts
at The Street - Wed Oct 30, 5:00AM CDT
Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
PR Newswire - Fri Sep 06, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced the 2nd Annual Sickle Cell Disease Therapeutics Conference will take place on September 19th, 2013 at the Four Seasons Hotel in New York City (Cosmopolitan Suite). The conference is intended to serve as a forum to raise awareness for sickle cell disease and will include presentations from leading companies in sickle cell disease and discussions with experts regarding the latest advancements and trends in treatment. Conference sponsors include The Pierre Fabre Foundation, Canaccord Genuity, Piper Jaffray, Sheppard Mullin Richter & Hampton, LLP, Pharm-Olam International and Theradex Systems, Inc.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista") announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 06, 12:39PM CST
These under-$10 stocks look ready to trade higher from current levels.
Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"), a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial."
Mast Therapeutics acquires Aires Pharmaceuticals in all-stock transaction
M2 - Fri Feb 28, 3:43AM CST
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) disclosed on Thursday the completion of the acquisition of Aires Pharmaceuticals in an all-stock transaction.
Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
PR Newswire - Thu Feb 27, 1:18PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension.
Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd
PR Newswire - Tue Feb 25, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen & Co. 34th Annual Healthcare Conference on Monday, March 3, 2014 at 4:50 p.m. Eastern time at The Boston Marriott Copley Place Hotel in Boston.
Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188
PR Newswire - Mon Feb 24, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, consistent with its prior guidance, it has initiated international enrollment in EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, with clinical sites now open in multiple foreign jurisdictions with high rates of hospitalization for sickle cell disease. The Company previously reported that it had met its goal of having 40 U.S. sites open by the end of 2013 and is on-track to opening an additional 30 sites outside of the U.S. by the end of 2014.
Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
PR Newswire - Tue Feb 18, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 (low dose and high dose) in a model of chronic heart failure.
Mast Therapeutics to acquire Aires Pharmaceuticals
M2 - Tue Feb 11, 6:52AM CST
US-based biopharmaceutical company Mast Therapeutics Inc (NYSE MKT:MSTX) said on Monday that it has signed a definitive agreement to acquire Aires Pharmaceuticals Inc in exchange for Mast's common stock in an all-stock transaction.
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.
PR Newswire - Mon Feb 10, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.
Vista Partners Publishes February 2014 Macroeconomic & Investment Newsletter
Marketwire - Wed Feb 05, 8:01AM CST
Vista Partners ("Vista") announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of February. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
PR Newswire - Wed Jan 08, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided an update on the status of EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease. Consistent with prior guidance, the Company announced that 40 clinical sites were opened in the U.S. by year-end 2013. In addition, clinical sites are expected to open in at least three countries outside the U.S. in the first quarter of 2014, leading to a total of approximately 30 ex-U.S. sites open by the end of 2014. Overall study enrollment is consistent with internal projections and the Company affirmed prior guidance that it expects to complete full enrollment for the trial by the end of 2015.
Mast Therapeutics To Present At The OneMedForum Emerging Company Finance Conference On January 14
PR Newswire - Tue Jan 07, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the OneMedForum Emerging Company Finance Conference on Tuesday, January 14th, 2014 at 2:10 p.m. Pacific time at The Westin Hotel in San Francisco.
Mast Therapeutics Announces Positive Data In Model Of Heart Failure
PR Newswire - Mon Jan 06, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output. Notably, a single two-hour infusion of MST-188 resulted in improvements that were significant immediately (at the end of MST-188 administration) and remained significant at one week (and, in some cases, at two weeks) after MST-188 administration.
Vista Partners Updates Coverage on Mast Therapeutics, Inc.; Price Target $2.25
Marketwire - Wed Dec 18, 8:15AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"), a publicly traded biopharmaceutical company headquartered in San Diego, CA, with a twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "MSTX began dosing in its pivotal Phase 3 clinical study of MST-188 (purified poloxamer 188) in sickle cell disease in May. MSTX believes that it is currently the only company with a new molecular entity in a Phase 3 clinical trial for the treatment of sickle cell disease, a disease with significant unmet needs and which has been experiencing unprecedented interest from strategic partners, acquisition oriented suitors, and financial investors." Mr. Silver continued, "MSTX plans to develop MST-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease. Peripheral arterial disease affects an estimated 8 to 12 million people in the United States. The planned Phase 2 trial in ALI is scheduled to commence in the first quarter of 2014." Mr. Silver concludes, "MSTX anticipates that cash as of September 30, 2013 or $0.48/share, should be sufficient to fully fund all planned clinical trials."
Mast Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3
PR Newswire - Tue Nov 26, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 25th Annual Piper Jaffray Healthcare Conference, on Tuesday, December 3rd, 2013 at 4:30 p.m. Eastern time in the Rutherford Room at The New York Palace Hotel in New York.
FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
PR Newswire - Wed Nov 13, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the U.S. Food and Drug Administration (FDA) has designated MST-188 for the treatment of acute limb ischemia as an orphan drug.
Mast Therapeutics Reports Third Quarter 2013 Financial Results
PR Newswire - Mon Nov 04, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended September 30, 2013.
5 Stocks Under $10 on the Verge of Breakouts
at The Street - Wed Oct 30, 5:00AM CDT
Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
PR Newswire - Fri Sep 06, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced the 2nd Annual Sickle Cell Disease Therapeutics Conference will take place on September 19th, 2013 at the Four Seasons Hotel in New York City (Cosmopolitan Suite). The conference is intended to serve as a forum to raise awareness for sickle cell disease and will include presentations from leading companies in sickle cell disease and discussions with experts regarding the latest advancements and trends in treatment. Conference sponsors include The Pierre Fabre Foundation, Canaccord Genuity, Piper Jaffray, Sheppard Mullin Richter & Hampton, LLP, Pharm-Olam International and Theradex Systems, Inc.
